Biogen Pharmachem Industries Ltd

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Biogen Pharmachem Industries Ltd’s stock price declined sharply on 03 Jun 2026, hitting a new 52-week low of Rs.0.33, marking a significant downturn in the company’s market performance amid broader sector and market pressures.

A sharp decline of 8.11% today dragged Biogen Pharmachem Industries Ltd to a fresh 52-week low of Rs 0.34, extending its downward trajectory amid persistent selling pressure despite a broadly positive market backdrop.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 21 May 2026, providing investors with the latest insights into its performance and prospects.

Biogen Pharmachem Industries Ltd’s stock price reached a new 52-week low of Rs.0.36 on 21 May 2026, marking a significant decline amid ongoing financial pressures and subdued market performance within the Non Banking Financial Company (NBFC) sector.

Biogen Pharmachem Industries Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has seen a marked deterioration in its valuation metrics, prompting a downgrade to a Strong Sell rating. With its price-to-earnings (P/E) ratio soaring to 45.45 and price-to-book value (P/BV) plummeting to 0.44, the stock’s price attractiveness has shifted from very expensive to risky, raising concerns among investors amid weak returns and poor profitability indicators.

Biogen Pharmachem Industries Ltd., a micro-cap non-banking financial company, reported a net loss of ₹0.36 crores in Q4 FY26, marking a sharp reversal from the ₹0.46 crores profit recorded in the previous quarter. The loss represents a deterioration of 178.26% on a quarter-on-quarter basis and a 130.51% decline year-on-year compared to the ₹1.18 crores profit in Q4 FY25. With a market capitalisation of just ₹42.00 crores and the stock trading at ₹0.39, the company faces mounting operational challenges that have eroded investor confidence.

A sharp decline over the past three sessions has dragged Biogen Pharmachem Industries Ltd to a fresh 52-week low of Rs 0.38 on 15 May 2026, marking a 56.04% drop over the last year and signalling sustained pressure on this micro-cap NBFC stock despite broader market gains.

Despite a broadly positive market mood with the Sensex gaining 0.27% today, Biogen Pharmachem Industries Ltd has plunged to a fresh 52-week low of Rs 0.41, extending its recent downward trajectory amid persistent selling pressure.

A sharp decline has pushed Biogen Pharmachem Industries Ltd to a fresh 52-week low of Rs 0.42 on 13 May 2026, marking a significant 61% drop from its peak of Rs 1.08 within the last year. This downturn comes despite some improvement in profitability, highlighting a complex interplay of valuation and market sentiment pressures.

Despite a broad market rally and sectoral strength, Biogen Pharmachem Industries Ltd has plunged to a fresh 52-week low of Rs 0.43 on 11 May 2026, extending its recent downward trajectory amid persistent selling pressure.

A sharp decline in Biogen Pharmachem Industries Ltd has pushed the stock to a fresh 52-week low of Rs 0.44 on 8 May 2026, marking a 47.06% drop over the past year and signalling intensified selling pressure despite some recent gains in the broader market indices.

Biogen Pharmachem Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Sep 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are current as of 08 May 2026, providing investors with an up-to-date view of the company’s position in the market.

Biogen Pharmachem Industries Ltd’s stock price declined to a fresh 52-week low of Rs.0.46 on 05 May 2026, marking a significant downturn amid broader market pressures and company-specific financial indicators. The stock’s performance over the past year has been notably weaker than the benchmark Sensex, reflecting ongoing concerns about its financial health and valuation metrics.

A sharp decline has pushed Biogen Pharmachem Industries Ltd to a fresh 52-week low of Rs 0.46 on 28 Apr 2026, marking a 47.25% drop over the past year and underscoring persistent selling pressure despite pockets of financial improvement.